Skip to main content
. 2022 Feb 6;14(3):826. doi: 10.3390/cancers14030826

Table 4.

Best response achieved with AML treatment. Italy, 2013–2021.

Best Response No. (%)
Complete response 31 (15.6%)
Partial response 57 (28.6%)
Total responders 88 (44.2%)
Stable disease 57 (28.6%)
Disease progression 5 (2.5%)
Total non-responders 62 (31.2%)
Not evaluable a 49 (24.6%)

a Including 11 patients with hematological improvement and 38 patients considered “not evaluable” by clinicians (31 of them had undergone less than 4 therapy cycles).